XTALPI-P Announces Strategic Collaboration with JW Pharmaceutical to Build Next-Generation AI and Robotics-Powered Drug Synthesis Laboratory

Feb 04, 2025 10:06 CST Updated 10:06

XtalPi

Computation-Driven Innovative Drug R&D Provider

JW Pharmaceutical

Pharmaceutical Company

Today, XtalPi (XtalPi Holdings Limited, XTALPI-P, 2228.HK) announced the signing of an agreement with JW Pharmaceutical (001060.KS), a leading pharmaceutical company in Asia based in South Korea.Tens of Millions of RMBStrategic cooperation agreement. XtalPi willProvide JW with a set of drug discovery automation workstations and an AI-based chemical reaction optimization platform., to comprehensively empower JW's drug research and development efficiency, reproducibility, and success rate. This collaboration represents a cutting-edge practice of deep integration of artificial intelligence and automated experiments in the field of drug discovery, highlighting JW's commitment and investment in technological innovation and industry advancement.

According to the agreement, XtalPi will deploy a series of high-throughput automated synthesis workstations, AI reaction condition optimization systems, and intelligent analysis platforms for JW Pharmaceutical to meet JW's complex R&D needs in automated drug candidate molecule screening, synthesis, and process optimization. By leveraging Bayesian optimization, digital management, and automated laboratory technologies, this solution is expected to effectively improve the success rate and reproducibility of chemical synthesis, shorten the drug development cycle, reduce R&D costs, and enhance the efficiency of new drug discovery. Relying on automation and standardized data processing capabilities, XtalPi's automated platform, as a new generation of infrastructure combined with years of technical accumulation and collaboration with JW Pharmaceutical, is poised to set a successful benchmark for AI-driven drug discovery.

XtalPi's High-Throughput Automated Synthesis Lab is a Key Component of its AI for Science R&D Platform

At the same time, XtalPi has successfullySinopec、Fudan University、Traditional Chinese Medicine Guangdong Provincial Laboratory (referred to as "Hengqin Laboratory")(ClickView more)...and other leading customers across multiple fields have signed purchase contracts for automated laboratory systems and completed on-site delivery. This cooperation with JW Pharmaceutical marks the first time that XtalPi's automated laboratory solution has been procured by an overseas pharmaceutical company, which is a significant milestone.

Dr. Park Chan-hee, Chief Technology Officer of JW Pharmaceutical, stated"At a time when the costs and challenges of innovative drug development are increasing, JW Pharmaceutical's choice to partner with XtalPi is based on the innovative advantages brought by XtalPi’s unique AI + robotics technology combination. We highly value XtalPi’s automated platform, which can handle thousands of synthesis experiments daily, as well as its AI models' ability to rapidly iterate, optimize JW compounds, and design synthetic pathways. This will build a solid technological foundation for breakthrough pipeline development in areas such as oncology and metabolic diseases, accelerating the entry of more competitive drugs into clinical research."

XtalPi CEO Dr. Ma Jian pointed out: “This collaboration has established a new paradigm of innovative cooperation in the field of AI-driven drug discovery between China and South Korea, serving as a strong endorsement of our technological capabilities. Our self-developed AI platform, trained on proprietary accumulated data, is progressively improving its success rate in predicting chemical reactions. Combined with modular robotic workstations, it enables partners to achieve closed-loop iterations of molecular design, synthesis, and testing with higher throughput and precision. The partnership with JW Pharmaceutical will allow XtalPi's AI + robotics foundational technologies to more directly empower source innovation for new drug development in Asia. This marks an important step for XtalPi in expanding its presence in the Asia-Pacific market and holds the potential to bring high-quality and efficient drugs to more patients.

In 2023, C&C Research Laboratories, a subsidiary of JW Pharmaceutical, signed a new drug research and development service agreement with XtalPi. Targeting the STAT6 target selected by C&C Research Laboratories, the two parties successfully discovered a series of lead compounds with high activity and desirable drug-like properties and advanced their development. The upgraded cooperation between JW Pharmaceutical and XtalPi marks an advanced practical case of intelligent and automated upgrades in drug research and development in Asia, bringing more possibilities for the application of artificial intelligence technologies and the development of the pharmaceutical industry in South Korea.

● AboutJW Pharmaceutical ●

JW Pharmaceutical is a leading pharmaceutical company in Asia, focusing on the research and production of anti-cancer drugs, immunotherapy, and treatments for rare diseases. With innovation as its core driving force, the company is committed to advancing the future of healthcare through cross-disciplinary collaboration and cutting-edge technological breakthroughs, bringing healthier and happier lives to humanity.

As a leader and pioneer in the healthcare field, JW has always adhered to the vision of "achieving today's impossibilities and creating tomorrow’s possibilities through innovative technology." It actively invests in the research and application of advanced technologies, continuously pushing the boundaries of drug development. Through global strategic planning, JW has steadily expanded its market influence and achieved historic performance growth in 2023, becoming South Korea's pharmaceutical company with the highest profit margin, further solidifying its outstanding position and industry leadership in the pharmaceutical markets of South Korea and globally.